Irritable Bowel Syndrome (IBS) Clinical Trial
Official title:
A Randomized Controlled Trial Comparing a Collaborative Cognitive Behavioral Therapy / Hypnotherapy Program to Standard Medical Management in the Treatment of Pediatric Functional Gastrointestinal Disease
This program has been created to help patients with irritable bowel syndrome manage their symptoms and increase their functioning by using cognitive therapy skills and hypnosis.
Functional Gastrointestinal Diseases (FGID) are a family disorders that are characterized by
gastrointestinal symptoms in the absence of readily identifiable organic pathology. Examples
of FGID include irritable bowel syndrome, rumination syndrome, and function constipation.
These disorders are classically thought to stem from dysfunction of the enteric nervous
system. However, there is a growing recognition that multiple factors play a role in the
genesis of FGIDs. This idea is encapsulated by the "biopsychosocial" model of disease, and is
supported by a body of literature which has identified higher rates of FGID in patients with
anxiety, depression, post-traumatic stress disorder, agoraphobia, and other psychosocial
dysfunction.
Recurrent Abdominal Pain and Irritable Bowel Syndrome are major causes of pediatric
morbidity. Over a third of children and adolescents report recurrent abdominal pain, and the
overall prevalence of non-organic abdominal pain has been noted to be over 75% 1 2. A large
subset of these children report symptoms that are consistent with irritable bowel syndrome.
Management of these children is complex and includes medical, dietary, and behavioral
interventions. Medical therapy often revolves around the use of antispasmodics, probiotics,
and antidepressants. The data supporting their use, however has been mixed.
Over the last twenty years behavioral therapies such as cognitive behavioral therapy (CBT)
and hypnotherapy (HT) have come to light as major treatment modalities for functional
gastrointestinal disease. In a large multicenter randomized controlled trial Levy et al
compared 3-session CBT to a control intervention and noted significant improvements and pain
and function in children 3. Similar results have been published in multiple smaller trials
4-8. Likewise, Vlieger et al compared hypnotherapy to standard medical therapy in 53 children
with irritable bowel syndrome. They found that, while both interventions resulted in improved
pain scores, the hypnotherapy group demonstrated lasting clinical improvement at 1 year
followup 9. Five year follow-up data has recently been published and revealed that
significantly more of the hypnotherapy group remained in remission without any further
intervention 10. A growing body of literature is available validating the use of hypnotherapy
in irritable bowel syndrome in adults, and pain syndromes more generally 11-14.
These therapies can be viewed as complementary to one another. CBT involves a very deliberate
conscious understanding of ones disease process and triggers and focuses on successful pain
mitigation measures. HT recruits the imagination with utilization of therapeutic imagery to
down regulate inappropriate pain responses. Our center has developed a collaborative
approach, utilizing both CBT and HT for the treatment of refractory IBS. To our knowledge no
work has been done assessing the efficacy of such a collaborative approach using both CBT and
HT in children with functional gastrointestinal disease. We therefore propose the following
randomized case-control crossover trial to assess the efficacy our combined program.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02841878 -
Genetic Determinism of Epithelial Barrier Defects in Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT02875847 -
Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS Patients
|
Phase 2 | |
Completed |
NCT02842281 -
Microbiome Fructan Metabolism and Symptoms in Childhood IBS
|
N/A | |
Completed |
NCT02092402 -
Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03964103 -
qQ-lab Daily-IBS for Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT00401479 -
A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00421707 -
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT06139744 -
Efficacy and Safety of Dietary Supplementation of Diamine Oxidase to Improve Symptoms in Patients With IBS
|
Phase 4 | |
Recruiting |
NCT04506593 -
Indiana University Gastrointestinal Motility Diagnosis Registry
|
||
Completed |
NCT01908465 -
Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial
|
Phase 4 | |
Completed |
NCT01787253 -
Microbe-Gut Interaction in Microscopic Colitis and Post-Infectious Irritable Bowel Syndrome (IBS)
|
||
Completed |
NCT00376896 -
Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00904696 -
Tolerability and Effectiveness of Progut in Treatment of Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT05453084 -
Exercise and Irritable Bowel Syndrome (IBS)
|
N/A | |
Completed |
NCT03550742 -
Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients
|
N/A | |
Terminated |
NCT01887002 -
Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
|
Phase 2 | |
Completed |
NCT01774695 -
Physical Activity in IBS - a Long Term Follow up
|
N/A | |
Completed |
NCT01204515 -
Abdominal Symptom Phenotype Study in Children
|
N/A | |
Completed |
NCT00067457 -
Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
|
Phase 3 | |
Completed |
NCT00067561 -
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
|
Phase 3 |